AHA 2024: GLP-1R agonist associated with better clinical outcomes in heart failure and CKD
Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...
AHA 2024: semaglutide continues to impress in diabetic kidney disease
KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...
Exenatide, a GLP-1 analog, by IV during cardiac surgery did not reduce organ injury or death
A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog ...
'Staggeringly high' discontinuation rates for GLP-1 drugs like Ozempic or Wegovy
The use of diabetes and weight-loss medications like Ozempic or Wegovy—called GLP-1 drugs—has exploded in recent years, with ...